Inspire Medical Systems (NYSE: INSP) appoints AtriCure CEO Michael Carrel to board
Rhea-AI Filing Summary
Inspire Medical Systems, Inc. appointed Michael H. Carrel to its Board of Directors as a Class III director, effective July 20, 2026. His term runs until the company’s 2027 Annual Meeting of Stockholders, and he will also serve on the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee.
Carrel is President, Chief Executive Officer and director of AtriCure, Inc. and has held multiple leadership roles at publicly traded healthcare and technology companies. Under the Non-Employee Director Compensation Policy, he will receive a $55,000 annual cash board retainer, $7,500 annually for each committee, a $300,000 initial restricted stock unit grant vesting over three years, and $200,000 in annual RSU awards following each annual meeting, plus standard director indemnification.
Positive
- None.
Negative
- None.
Filing Explained
Carrel’s appointment is effective, but the compensation terms create additional common-stock mechanics: he may elect cash retainers as shares, while the
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Annual board cash retainer: $55,000
Committee cash retainers: $7,500 + $7,500
Initial RSU award: $300,000
+3 more
6 metrics
Annual board cash retainer
$55,000
Annual cash retainer for serving on the Board, earned quarterly
Committee cash retainers
$7,500 + $7,500
Annual cash retainers for Organization and Compensation and Quality, Product Supply and Technology Committees
Initial RSU award
$300,000
Initial equity-based restricted stock unit award, vesting over three years
Annual RSU award
$200,000
Equity-based RSU award following each annual meeting, vesting after one year
Director term
2027 Annual Meeting
Class III director term expires at the 2027 Annual Meeting of Stockholders
Appointment effective date
July 20, 2026
Date Michael H. Carrel was appointed to the Board
Key Terms
Class III director, Non-Employee Director Compensation Policy, restricted stock units, Annual Meeting of Stockholders, +1 more
5 terms
Class III director regulatory
"will serve as a Class III director for a term expiring at the Company’s 2027"
A Class III director is a board member placed in one of the numbered groups used by companies with a staggered (or “classified”) board; that director’s seat typically comes up for election in the third year of a three-year rotation. For investors this matters because staggered terms create continuity but also make it harder to replace the whole board quickly, affecting shareholder influence, takeover dynamics and how fast new strategy or accountability can be implemented — like replacing only some players on a sports team each season instead of the whole roster at once.
Non-Employee Director Compensation Policy financial
"Mr. Carrel is eligible to participate in the Company’s Non-Employee Director Compensation Policy"
restricted stock units financial
"initial equity-based award of restricted stock units to acquire shares of the Company’s"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Annual Meeting of Stockholders regulatory
"term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his successor"
indemnification agreement regulatory
"entitled to indemnification against certain liabilities, costs, and expenses in accordance with the Company’s standard indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board change did Inspire Medical Systems (INSP) disclose?
Inspire Medical Systems appointed Michael H. Carrel to its Board of Directors as a Class III director, effective July 20, 2026. His term runs until the 2027 Annual Meeting of Stockholders, and he will serve on two key board committees.
What is Michael H. Carrel’s background relevant to Inspire Medical Systems (INSP)?
Michael H. Carrel is President, CEO and director of AtriCure, Inc., a medical device company. He previously led Vital Images and Zamba Corporation and served as CFO of NextNet Wireless, adding broad healthcare and technology leadership experience.
How will new director Michael H. Carrel be compensated at Inspire Medical Systems (INSP)?
Carrel will receive a $55,000 annual cash board retainer, $7,500 annually for each of two committees, a $300,000 initial RSU grant vesting over three years, and $200,000 in RSUs after each annual meeting, subject to continued board service.
What equity awards will Michael H. Carrel receive from Inspire Medical Systems (INSP)?
He is eligible for an initial restricted stock unit award worth $300,000, vesting in equal annual installments over three years. After each annual stockholders’ meeting, he may receive an additional $200,000 RSU award vesting on the first anniversary of grant.
Which board committees will Michael H. Carrel join at Inspire Medical Systems (INSP)?
Carrel was appointed to the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee. He will receive separate annual cash retainers of $7,500 for each committee role, earned on a quarterly basis.